

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

#### Drug Advisory Committee October 2024 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
1	Acalabrutinib	Calquence	Malignant disease and immunosuppression	Approved	
2	Andexanet alfa	Andexxa	Drugs for treating poisoning	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
3	Apalutamide	Erleada	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
4	Belumosudil	Rezurock	Malignant disease and immunosuppression	Approved	
5	Belzutifan	Welireg	Malignant disease and immunosuppression	Approved	
6	Blinatumomab	Blincyto	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
7	Carglumic acid	Carbaglu	Nutrition and blood	Approved	
8	Corifollitropin alfa	Elonva	Endocrine system	Approved	
9	Daratumumab / Lenalidomide	Darzalex/Revlimid	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
10	Darolutamide	Nubeqa	Malignant disease and immunosuppression	Approved	
11	Dupilumab	Dupixent	Skin / Respiratory system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient / Major budget impact
12	Durvalumab	Imfinzi	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
13	Durvalumab / Tremelimumab	Imfinzi/Imjudo	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
14	Enfortumab vedotin	Padcev	Malignant disease and immunosuppression	Approved	
15	Glofitamab	Columvi	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
16	Iptacopan	Fabhalta	Nutrition and blood	Approved	
17	Ketoprofen patch	Mohrus patch	Musculoskeletal and joint disease	Rejected	Alternative(s) available in HADF with comparable benefits

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
18	Liraglutide	Saxenda	Endocrine system	Rejected	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population
19	Maralixibat	Livmarli	Gastro-intestinal system	Rejected	Insufficient evidence of long-term clinical outcome benefits
20	Niraparib	Zejula	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population
21	Nivolumab / Ipilimumab	Opdivo / Yervoy	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
22	Olaparib	Lynparza	Malignant disease and immunosuppression	Approved	
23	Pralsetinib	Gavreto	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
24	Ravulizumab	Ultomiris	Nutrition and blood	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient / Insufficient evidence of long-term clinical outcome benefits
25	Sacituzumab Govitecan	Trodelvy	Malignant disease and immunosuppression	Approved	
26	Selinexor	Xpovio	Malignant disease and immunosuppression	Approved	
27	Selpercatinib	Retsevmo	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
28	Spesolimab	Spevigo	Skin	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
29	Tafamidis	Vyndamax	Cardiovascular system	Approved	
30	Tafasitamab / Lenalidomide	Minjuvi/Revlimid	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
31	Upadacitinib	Rinvoq	Gastro-intestinal system	Approved	
32	Velmanase alfa	Lamzede	Nutrition and blood	Pending	Pending further information

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.